Premium
Effectiveness, Tolerability, and Safety of Topiramate in Children with Partial‐Onset Seizures
Author(s) -
Ritter Frank,
Glauser Tracy A.,
Elterman Roy D.,
Wyllie Elaine
Publication year - 2000
Publication title -
epilepsia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.687
H-Index - 191
eISSN - 1528-1167
pISSN - 0013-9580
DOI - 10.1111/j.1528-1157.2000.tb02178.x
Subject(s) - topiramate , tolerability , medicine , adverse effect , concomitant , dose , placebo , pediatrics , anesthesia , epilepsy , partial seizures , anticonvulsant , adjunctive treatment , surgery , psychiatry , alternative medicine , pathology
Summary: Purpose : Children with partial‐onset seizures, with or without secondary generalization, participating in a double‐blind, placebo‐controlled trial of topiramate (TPM) as adjunctive therapy were eligible to participate in an open‐label, long‐term extension study. Methods : A total of 83 children (mean age, 9 years) continued long‐term open‐label TPM therapy in which the dosages of TPM and concomitant antiepileptic drugs (AEDs) were adjusted according to clinical response (mean TPM dosage, 9 mg/kg/day). Results : Seizure frequency over the last 3 months of therapy was reduced ges;50% in 57% of children; 14% of children were seizure‐free ges;6 months at the last visit. During treatment periods up to 2 1/2 years (mean, 15 months), 6% of children discontinued because of treatment‐emergent adverse events; 13% discontinued because of inadequate seizure control. Conclusions : From these findings, TPM is well tolerated and provides long‐term seizure control in children with partial‐onset seizures.